About Humana (NYSE:HUM)
Humana Inc. is a health and well-being company. The Company's segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products. The Group and Specialty segment consists of employer group commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health. The Healthcare Services segment includes services offered to its health plan members, as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs, as well as services and capabilities to manage population health. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand.
Industry, Sector and Symbol
Industry MEDICAL CARE
Sub-IndustryManaged Health Care
Trailing P/E Ratio16.3507194244604
Forward P/E Ratio19.75
Sales & Book Value
Annual Sales$53.77 billion
Price / Sales0.70
Cash Flow$15.43 per share
Price / Cash17.68
Book Value$68.89 per share
Price / Book3.96
Net Income$2.45 billion
Return on Equity16.13%
Return on Assets5.49%
Humana (NYSE:HUM) Frequently Asked Questions
What is Humana's stock symbol?
Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."
How often does Humana pay dividends? What is the dividend yield for Humana?
Humana declared a quarterly dividend on Tuesday, February 6th. Shareholders of record on Friday, March 30th will be paid a dividend of $0.50 per share on Friday, April 27th. This represents a $2.00 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date of this dividend is Wednesday, March 28th. This is a boost from Humana's previous quarterly dividend of $0.40. View Humana's Dividend History.
How will Humana's stock buyback program work?
Humana declared that its board has approved a stock repurchase plan on Friday, December 15th 2017, which authorizes the company to buyback $3,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's leadership believes its stock is undervalued.
How were Humana's earnings last quarter?
Humana Inc (NYSE:HUM) released its quarterly earnings results on Wednesday, February, 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.06. The insurance provider had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. The company's quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.34 EPS. View Humana's Earnings History.
When will Humana make its next earnings announcement?
What guidance has Humana issued on next quarter's earnings?
Humana issued an update on its FY18 earnings guidance on Thursday, March, 1st. The company provided EPS guidance of $13.40-14.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $13.86.
Where is Humana's stock going? Where will Humana's stock price be in 2018?
18 brokers have issued 12 month price targets for Humana's shares. Their forecasts range from $221.00 to $305.00. On average, they anticipate Humana's stock price to reach $270.29 in the next year. View Analyst Ratings for Humana.
What are Wall Street analysts saying about Humana stock?
Here are some recent quotes from research analysts about Humana stock:
- 1. According to Zacks Investment Research, "Humana’s shares have outperformed the industry year to date. The company is well poised to grow on its strong government business. Its top line has been witnessing an uptrend for past many years. Sufficient generation of cash flow has helped the company take up several capital deployment initiatives aimed at enhancing shareholders’ value. Humana’s sound balance sheet and disciplined capital management remain major tailwinds. Following decent 2017 results, the company provided strong guidance for 2018. The company has seen the Zacks Consensus Estimate for 2018 earnings being revised upward in the last 60 days. However, the company's individual commercial business has remained a drag over past few years. Rising level of expenses also continues to weigh on the bottom line." (3/13/2018)
- 2. Cantor Fitzgerald analysts commented, "4Q17 results recap. 4Q17 revenue was $13 billion vs. our estimate of $13.8 billion and consensus of $13.2 billion. Retail segment revenue grew 3% and individual MA membership grew 1%. January 2018 individual MA membership grew about 5.7% from year end levels, which is impressive. Group MA membership grew nicely in 2017. January 2018 Group MA membership grew another 12% sequentially. MLR was slightly below our estimate and operating costs were essentially in line. 4Q17 EPS was $2.06 vs. our estimate of $1.97 and consensus of $2.00." (2/7/2018)
Who are some of Humana's key competitors?
Some companies that are related to Humana include Anthem (ANTM), Aetna (AET), Fresenius (FSNUY), Express Scripts (ESRX), HCA Healthcare (HCA), Cerner (CERN), Centene (CNC), Quest Diagnostics (DGX), Davita (DVA), Universal Health Services (UHS), Eurofins Scientifi (ERFSF), Nmc Health (NMHLY), WellCare Health Plans (WCG), Icon (ICLR), athenahealth (ATHN), PRA Health Sciences (PRAH), Encompass Health (EHC) and MEDNAX (MD).
Who are Humana's key executives?
Humana's management team includes the folowing people:
- Kurt J. Hilzinger, Independent Chairman of the Board (Age 57)
- Bruce D. Broussard, President, Chief Executive Officer, Director (Age 54)
- Brian A. Kane, Chief Financial Officer, Senior Vice President (Age 44)
- Timothy S. Huval, Chief Human Resource Officer, Senior Vice President (Age 50)
- Brian P. LeClaire, Senior Vice President, Chief Information Officer (Age 56)
- Sam Deshpande, Senior Vice President, Chief Risk Officer
- Christopher M. Todoroff, Senior Vice President, General Counsel (Age 54)
- Roy A. Beveridge M.D., Senior Vice President, Chief Medical Officer (Age 59)
- Jody L. Bilney, Senior Vice President, Chief Consumer Officer (Age 55)
- Christopher H. Hunter, Senior Vice President, Chief Strategy Officer (Age 48)
Who owns Humana stock?
Humana's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.39%), Renaissance Technologies LLC (2.35%), Wells Fargo & Company MN (1.29%), Bank of New York Mellon Corp (1.13%), Geode Capital Management LLC (1.11%) and TIAA CREF Investment Management LLC (0.95%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James E Murray, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.
Who sold Humana stock? Who is selling Humana stock?
Humana's stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Renaissance Technologies LLC, BlackRock Inc., Fred Alger Management Inc., American Century Companies Inc., Caisse DE Depot ET Placement DU Quebec, Old Mutual Global Investors UK Ltd. and Alliancebernstein L.P.. Company insiders that have sold Humana company stock in the last year include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, Elizabeth D Bierbower, Heidi S Margulis, Jody L Bilney, M Todoroff Christopher, Timothy S Huval and William Kevin Fleming. View Insider Buying and Selling for Humana.
Who bought Humana stock? Who is buying Humana stock?
Humana's stock was purchased by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Bank of Montreal Can, Virtus Fund Advisers LLC, Hudson Bay Capital Management LP, Wells Fargo & Company MN, NorthCoast Asset Management LLC, Teacher Retirement System of Texas and Bridger Management LLC. View Insider Buying and Selling for Humana.
How do I buy Humana stock?
Shares of Humana can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Humana's stock price today?
One share of Humana stock can currently be purchased for approximately $272.73.
How big of a company is Humana?
Humana has a market capitalization of $37.32 billion and generates $53.77 billion in revenue each year. The insurance provider earns $2.45 billion in net income (profit) each year or $16.68 on an earnings per share basis. Humana employs 45,900 workers across the globe.
How can I contact Humana?
Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000.
MarketBeat Community Rating for Humana (HUM)MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Humana (NYSE:HUM) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.78||2.78||2.58||2.63|
|Ratings Breakdown: ||0 Sell Rating(s)|
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$270.29||$270.29||$255.72||$243.44|
|Price Target Upside: ||0.89% downside||1.87% upside||0.43% upside||1.58% downside|
Humana (NYSE:HUM) Consensus Price Target History
Humana (NYSE:HUM) Analyst Ratings History
(Data available from 3/17/2016 forward)
Humana (NYSE:HUM) Earnings History and Estimates Chart
Humana (NYSE HUM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/7/2018||Q4 2017||$2.00||$2.06||$13.14 billion||$13.19 billion||View||Listen|
|11/8/2017||Q3 2017||$3.27||$3.39||$13.41 billion||$13.28 billion||View||N/A|
|8/2/2017||Q2 2017||$3.08||$3.49||$13.61 billion||$13.53 billion||View||Listen|
|5/3/2017||Q1 2017||$2.55||$2.75||$13.61 billion||$13.76 billion||View||N/A|
|2/8/2017||Q416||$2.05||$2.09||$13.55 billion||$12.88 billion||View||N/A|
|11/4/2016||Q316||$3.09||$3.18||$13.41 billion||$13.69 billion||View||N/A|
|8/3/2016||Q216||$2.23||$2.30||$13.59 billion||$14.00 billion||View||N/A|
|5/4/2016||Q1||$1.81||$1.86||$13.80 billion||$13.80 billion||View||N/A|
|2/10/2016||Q415||$1.45||$1.45||$13.51 billion||$13.40 million||View||N/A|
|11/6/2015||Q315||$2.13||$2.16||$13.64 billion||$13.36 billion||View||N/A|
|7/29/2015||Q215||$1.63||$1.67||$13.81 billion||$13.73 billion||View||N/A|
|4/29/2015||Q115||$2.54||$2.47||$13.51 billion||$13.80 billion||View||Listen|
|2/4/2015||Q414||$1.16||$1.09||$12.41 billion||$12.23 million||View||Listen|
|11/7/2014||Q314||$2.01||$1.85||$12.34 billion||$12.24 billion||View||Listen|
|7/30/2014||Q214||$2.19||$2.19||$11.93 billion||$12.22 billion||View||Listen|
|5/7/2014||Q114||$1.94||$2.35||$11.45 billion||$11.71 billion||View||Listen|
|2/5/2014||Q413||$0.95||($0.19)||$10.23 billion||$10.20 billion||View||Listen|
|11/6/2013||Q313||$2.14||$2.31||$10.27 billion||$10.00 billion||View||Listen|
|7/31/2013||Q2 2013||$2.46||$2.63||$10.36 billion||$10.32 billion||View||Listen|
|5/1/2013||Q1 2013||$1.80||$2.95||$10.23 billion||$10.49 billion||View||Listen|
|2/4/2013||Q4 2012||$1.07||$1.19||$9.73 billion||$9.56 billion||View||Listen|
|11/5/2012||Q312||$2.05||$2.62||$9.86 billion||$9.65 billion||View||N/A|
Humana (NYSE:HUM) Earnings Estimates
2018 EPS Consensus Estimate: $13.93
2019 EPS Consensus Estimate: $16.49
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Humana (NYSE:HUM) Dividend Information
|Dividend Growth:||10.60% (3 Year Average)|
|Payout Ratio:||9.59% (Trailing 12 Months of Earnings) |
11.59% (Based on This Year's Estimates)
9.71% (Based on Next Year's Estimates)
|Track Record:||7 Years of Consecutive Dividend Growth|
Humana (NYSE:HUM) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Humana (NYSE HUM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.60%
Institutional Ownership Percentage: 97.85%
Humana (NYSE HUM) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/9/2018||Cynthia H Zipperle||SVP||Sell||1,196||$273.33||$326,902.68||7,771|| |
|2/27/2018||M Todoroff Christopher||Insider||Sell||16,389||$273.37||$4,480,260.93||13,447|| |
|2/26/2018||Bruce D Broussard||CEO||Sell||14,075||$274.32||$3,861,054.00||113,896|| |
|12/21/2017||Brian P Leclaire||SVP||Sell||1,679||$245.97||$412,983.63||9,888|| |
|12/19/2017||Timothy S Huval||VP||Sell||1,382||$246.04||$340,027.28||11,557|| |
|12/18/2017||Jody L Bilney||SVP||Sell||7,054||$247.89||$1,748,616.06||11,704|| |
|9/1/2017||Elizabeth D Bierbower||Insider||Sell||9,786||$259.00||$2,534,574.00||18,042|| |
|9/1/2017||Timothy S Huval||VP||Sell||7,803||$258.14||$2,014,266.42||8,831|| |
|8/23/2017||William Kevin Fleming||Insider||Sell||3,071||$250.98||$770,759.58||7,681|| |
|8/11/2017||Bruce D Broussard||CEO||Sell||12,000||$251.88||$3,022,560.00||80,086|| |
|8/10/2017||M Todoroff Christopher||VP||Sell||22,935||$252.52||$5,791,546.20||24,001|| |
|6/28/2017||Brian P Leclaire||SVP||Sell||4,971||$240.00||$1,193,040.00||14,258|| |
|5/26/2017||Heidi S Margulis||VP||Sell||1,500||$231.96||$347,940.00||8,150|| |
|5/5/2017||Jody L Bilney||SVP||Sell||4,600||$230.16||$1,058,736.00||8,978|| |
|5/4/2017||Bruce D Broussard||CEO||Sell||118,231||$225.82||$26,698,924.42||171,170|| |
|5/4/2017||Timothy S Huval||VP||Sell||13,939||$225.86||$3,148,262.54||23,639|| |
|3/21/2017||Jody L Bilney||SVP||Sell||4,348||$213.80||$929,602.40||13,578|| |
|3/6/2017||James E Murray||COO||Sell||31,151||$213.62||$6,654,476.62||45,635|| |
|3/3/2017||Cynthia H Zipperle||VP||Sell||1,885||$213.37||$402,202.45||3,736|| |
|2/24/2017||Brian P Leclaire||SVP||Sell||4,971||$204.81||$1,018,110.51||14,258|| |
|2/22/2017||Brian P Leclaire||SVP||Sell||26,894||$205.24||$5,519,724.56||25,734|| |
|2/22/2017||James E Murray||COO||Sell||9,523||$204.69||$1,949,262.87||76,798|| |
|2/22/2017||Roy A Beveridge||VP||Sell||4,832||$205.73||$994,087.36||18,439|| |
|2/21/2017||Bruce D Broussard||CEO||Sell||104,256||$205.23||$21,396,458.88||155,108|| |
|2/21/2017||Cynthia H Zipperle||CAO||Sell||4,213||$204.67||$862,274.71||6,542|| |
|2/21/2017||David A. Jr/Ky Jones||Director||Sell||27,000||$205.04||$5,536,080.00|| |
|2/21/2017||James E Murray||COO||Sell||70,332||$205.20||$14,432,126.40||76,798|| |
|2/21/2017||Jody L Bilney||SVP||Sell||6,087||$204.72||$1,246,130.64||28,577|| |
|2/21/2017||M Todoroff Christopher||VP||Sell||24,140||$205.33||$4,956,666.20|| |
|2/25/2016||Brian P Leclaire||SVP||Sell||183||$176.11||$32,228.13||17,301|| |
|3/11/2015||James E Murray||COO||Sell||35,220||$160.90||$5,666,898.00|| |
|3/2/2015||Brian P Leclaire||SVP||Sell||5,500||$161.79||$889,845.00|| |
|2/25/2015||Bruce D Broussard||CEO||Sell||41,105||$165.29||$6,794,245.45|| |
|2/25/2015||David A Jr/Ky Jones||Director||Sell||6,100||$165.39||$1,008,879.00|| |
|2/24/2015||Heidi S Margulis||VP||Sell||3,665||$164.44||$602,672.60|| |
|8/22/2014||Brian P Leclaire||SVP||Sell||3,250||$123.04||$399,880.00|| |
|5/15/2014||Heidi Margulis||VP||Sell||3,345||$119.56||$399,928.20||8,730|| |
|5/12/2014||Marissa Peterson||Director||Sell||2,026||$123.30||$249,805.80||1,358|| |
|3/19/2014||James Murray||COO||Sell||36,833||$116.59||$4,294,359.47||89,892|| |
|3/18/2014||M Todoroff Christopher||VP||Sell||8,000||$113.20||$905,600.00||18,225|| |
|3/13/2014||Bruce Broussard||CEO||Sell||109,000||$109.84||$11,972,560.00||59,944|| |
|3/10/2014||Webster Roy Dunbar||Director||Sell||9,587||$110.30||$1,057,446.10||1,458|| |
|12/4/2013||Marissa Peterson||Director||Sell||1,147||$103.54||$118,760.38|| |
|12/2/2013||M Todoroff Christopher||VP||Sell||6,000||$105.50||$633,000.00||16,226|| |
|11/26/2013||Heidi Margulis||VP||Sell||5,500||$104.42||$574,310.00||7,136|| |
|11/8/2013||David Jr/Ky Jones||Director||Sell||11,000||$95.00||$1,045,000.00||143,339|| |
|9/5/2013||Elizabeth D Bierbower||Insider||Sell||17,673||$96.01||$1,696,784.73|| |
|8/30/2013||Heidi Margulis||VP||Sell||3,319||$93.35||$309,828.65||10,801|| |
|8/29/2013||David Jr/Ky Jones||Director||Sell||2,500||$93.01||$232,525.00||154,339|| |
|8/23/2013||Elizabeth Bierbower||Insider||Sell||6,063||$94.00||$569,922.00||16,473|| |
|8/15/2013||Michael Mccallister||Director||Sell||138,817||$91.49||$12,700,367.33||111,859|| |
|8/13/2013||Bruce Perkins||Insider||Sell||9,000||$93.47||$841,230.00||10,985|| |
|8/8/2013||Steven Mcculley||VP||Sell||10,000||$92.54||$925,400.00||9,327|| |
|8/7/2013||James Bloem||CFO||Sell||33,000||$91.79||$3,029,070.00||21,767|| |
|8/1/2013||M Todoroff Christopher||VP||Sell||39,596||$90.30||$3,575,518.80|| |
|6/24/2013||Paul B K Kusserow||SVP||Sell||34,219||$84.60||$2,894,927.40|| |
|6/18/2013||Elizabeth D Bierbower||Insider||Sell||8,033||$83.29||$669,068.57|| |
|5/30/2013||James E Murray||COO||Sell||11,000||$81.96||$901,560.00|| |
|5/9/2013||Michael B Mccallister||Director||Sell||281,312||$77.72||$21,863,568.64|| |
Humana (NYSE HUM) News Headlines
Humana (NYSE:HUM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Humana (NYSE:HUM) Income Statement, Balance Sheet and Cash Flow Statement
Humana (NYSE HUM) Stock Chart for Saturday, March, 17, 2018